

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER FILING I		DATE	FIRST NAMED APPLICANT			RNEY DOCKET NO.	
08/178	3,463	01/06/94	WILSON		W	20264034US	
				GOL	GOLDONNIS J		
			12M270516			1	

WILLIAM S. FEILER MORGAN & FINNEGAN 345 PARK AVE. NEW YORK, NY 1015

GOLDER	GOLDØERGS J					
ART UNIT	PAPER NUMBER					
1205	ラ ユ					
DATE MALLED						

05/16/95

Below is a communication from the EXAMINER in charge of this application COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

					ADVISOR	ACTION						
2	Т НІ	E PERIO	DD FOR RESI	PONSE:								
a)		is exter	nded to run _		or continues to run_	from	the date of the final	rejection				
b)	expires three months from the date of the final rejection or as of the mailing date of this Advisory Action, whichever is later. In no event however, will the statutory period for the response expire later than six months from the date of the final rejection.											
	Any extension of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate fee. The date on which the response, the petition, and the fee have been filed is the date of the response and also the date for the purposes of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR 1.17 will be calculated from the date of the originally set shortened statutory period for response or as set forth in b) above.											
D ₂	Ap	pellant's	Brief is due i	accordance with	37 CFR 1.192(a).							
	Ap _l to p	plicant's place the	response to t e application i	he final rejection, n condition for allo	filed wance:	has been considered	with the following e	ffect, but it is not deem	ned			
1.	1. The proposed amendments to the claim and /or specification will not be entered and the final rejection stands because:											
			There is no cor presented.	nvincing showing	under 37 CFR 1.116(b) why the proposed ame	ndment is necessary	and was not earlier				
		ь. 🔲 Т	hey raise new	issues that would	d require further consid	deration and/or search. (See Note).					
		c. 🔲 7	They raise the	issue of new mat	er. (See Note).							
			They are not appeal.	deemed to place t	he application in bette	r form for appeal by mate	erially reducing or sir	mplifying the issues for	•			
		е. 🔲	They present	additional claims v	vithout cancelling a co	rresponding number of fi	nally rejected claims	i.				
		NOTE:										
2.			proposed or a n-allowable cla		wo	ould be allowed if submitte	ed in a separately file	ed amendment cancel	ling			
3.	8	Upon t		peal, the propose	d amendment 🛂 will	be entered will not l	pe entered and the s	status of the claims will	I			
		Claims	allowed: objected to: _ rejected: However;	wone wone								
		☐ Ar	oplicant's resp	onse has overcom	e the following rejection	on(s):						
4.	₽	_de	fidavit, exhibit Lavati Lads	in is ba	onsideration has been	considered but does not	overcome the rejec	tion because <u>Cha</u>	<u>b</u> war			
5.		The aff		it will not be consi	dered because applica	ant has not shown good a	and sufficent reasons	s why it was not earlie	or 1			
_			ed drawing co	rrection has	has not been ap	proved by the examiner.	100		>			
ш	Oth	e:					// J	EROME D. GOLDBE	RG			

JEROME D. GOLDBERG PRIMARY EXAMINER GROUP 1200 Serial No. 08/178,463

Art Unit 1205

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. § 103, the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 C.F.R. § 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of potential 35 U.S.C. § 102(f) or (g) prior art under 35 U.S.C. § 103.

Claims 1 and 3-11 are rejected under 35 U.S.C. § 103 as being unpatentable over the Rowinsky et al., Holmes et al. and Gilman et al. reference of record. The Rowinsky et al. teaches the applicant' taxol for 24 hours of 200-250mg/m² by i.v. infusion. Applicants are employing taxol for 36 hours at the Holmes et al. reference teaches taxol for treating breast cancer at 250mg/m² for 24 hours infusion every 21 days. The Gilman et al. reference teaches 30mg/m² per day for 5 days or 210mg - 250mg

Serial No. 08/178,463

Art Unit 1205

given every 3 weeks. Applicants are employing taxol for 96 hours at 140mg/m² by i.v. infusion. The difference is in the number of hours and the amount being employed. In view of this, one skilled in the art could be motivated to employ the i.v. infusion of the prior art for a long period of time in the absence of a side-by-side comparison.

Claims 1 and 3-11 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1 and 3-11 are improperly drawn to two different steps. The step of preparing an infusion solution and the step of infusion. The terms "at least 24 hours" in claims 1, 3 and 4 and "at least 96 hours" in claims 6-9 is indefinite in failing to recite an upper limit.

A facsimile center has been established in Group 1200, room 3C10. The hours of operation are Monday through Friday, 8:45 AM to 4:45 PM. The telecopier numbers for accessing the facsimile machines are (703) 308-4556 or 305-3592.

Any inquiry concerning this communication should be directed to Examiner Goldberg at telephone number (703) 308-1235.

GOLDBERG:jd April 08, 1994 JEROME D. GOLDBERG PRIMARY EXAMINER GROUP 1200